Bayer Sp. z o.o.
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Our products and services are designed to benefit people and improve their quality of life. At the same time, we aim to create value through innovation, growth and high earning power.
Our products help address some of today's biggest challenges, including global population growth, an aging society and the need to make efficient – and, wherever possible, sustainable – use of natural resources.
In line with our mission "Bayer: Science For A Better Life," we aim to improve people's quality of life by preventing, alleviating or curing diseases. We also help provide an adequate supply of high-quality food, feed and renewable plant-based raw materials. For these endeavors, we focus on developing and successfully commercializing innovative products and solutions based on scientific knowledge.
- Focus : Manufacturer
- Industry : Pharma
Products from Bayer
News about Bayer
08-Mar-2023 | Cooperation
New organ-on-chip pilot seeks to reduce animal testing in consumer health industry
A first-of-its-kind collaboration in the consumer health industry is developing a platform aimed at reducing or replacing animal testing using “organ-on- ...
28-Feb-2023 | Finances
Bayer: Significant growth in sales and earnings
The Bayer Group achieved strong growth last year, posting significantly higher sales and earnings. “2022 was a very successful year for Bayer despite the ...
09-Feb-2023 | People
Bill Anderson to become CEO of Bayer AG
The Supervisory Board of Bayer AG has appointed Bill Anderson to become CEO of Bayer, effective June 1, 2023. He will join Bayer as a member of the Board ...
12-Jan-2023 | Cooperation
Bayer to Accelerate Drug Discovery with Google Cloud’s High-Performance Compute Power
Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud’s Tensor Processing Units (TPUs), which are ...
12-Jan-2023 | Finances
NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B ...
14-Nov-2022 | Business
Bayer Acquires German Biotech Start-up Targenomix
Bayer announced the acquisition of German biotech start-up Targenomix. The spin-off of the Max Planck Institute for Molecular Plant Physiology (MPI MPP) ...
08-Nov-2022 | Finances
Bayer with continued strong performance
The Bayer Group maintained its strong business performance across all three divisions in the third quarter. “Despite rising inflation and global supply ...